NCT06192680View on ClinicalTrials.gov

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

September 30, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

Liposomal irinotecan

70 mg/m² IV

DRUG

Capecitabine

1000 mg/m² PO BID

DRUG

Bevacizumab

5mg/kg IV

All Listed Sponsors
lead

Harbin Medical University

OTHER